REVIEW article
Front. Cell Dev. Biol.
Sec. Stem Cell Research
This article is part of the Research TopicMesenchymal Stromal Cells: Biology, Therapeutic Potential, and Translational ChallengesView all 3 articles
Mesenchymal Stromal Cell Therapy in Epidermolysis Bullosa: Current Perspectives and Future Directions
Provisionally accepted- 1Laboratory for Advancements in Precision Delivery (LAPD), Stanford University School of Medicine, Department of Radiology, Palo Alto, United States
- 2Center for Interventional Radiology Innovation at Stanford (IRIS), Stanford University School of Medicine, Palo Alto, United States
- 3Stanford University School of Medicine, Department of Dermatology, Palo Alto, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Epidermolysis bullosa (EB) is a group of inherited mucocutaneous disorders. Mesenchymal stromal cells (MSCs) are non-hematopoietic self-renewing, multipotent cells that are a promising therapeutic avenue for EB, given their ability to home to injury, low immunogenicity, and demonstrated wound-healing, anti-fibrotic, and pro-collagen effects. This review article synthesizes the current literature and advancement on MSC therapy in EB, and highlights the potential to optimize their use, including exploring MSC-derived extracellular vesicles as a potential cell-free therapy. Innovative delivery methods can also improve the accessibility and effectiveness of MSC therapies by providing localized treatment, minimizing systemic side effects, and increasing patient comfort.
Keywords: Epidermolysis Bullosa, Mesenchymal Stem Cells, Mesenchymal Stromal Cells, extracellular vesicles, Therapeutics
Received: 10 Sep 2025; Accepted: 29 Oct 2025.
Copyright: © 2025 Sia, Primavera, Johnson, Dukkipati, Teng and Thakor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Avnesh  S Thakor, asthakor@stanford.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
